A Study of Intravenous Tamiflu (Oseltamivir) in Children With Influenza
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This open-label study will assess the pharmacokinetics/pharmacodynamics and safety of
intravenous (iv) Tamiflu (oseltamivir) in 3 cohorts of children, aged 6-12, 3-5 and 1-2
years, with influenza infection. Patients will receive iv Tamiflu therapy for 5 days (10
doses). For patients whose conditions no longer merit continued iv dosing, therapy may be
switched to oral Tamiflu to complete their prescribed course of treatment. If medically
necessary, iv or oral therapy with Tamiflu may be continued for up to 5 additional days.
Anticipated time on study treatment is 5 to 10 days.